BNP Paribas Financial Markets’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $37M | Buy |
301,472
+106,942
| +55% | +$11.2M | 0.01% | 916 |
|
|
2026
Q1 | $20.5M | Buy |
194,530
+96,766
| +99% | +$8.57M | 0.01% | 1135 |
|
|
2025
Q4 | $8.54M | Buy |
97,764
+84,627
| +644% | +$6.93M | ﹤0.01% | 1713 |
|
|
2025
Q3 | $873K | Buy |
13,137
+3,998
| +44% | +$227K | ﹤0.01% | 3213 |
|
|
2025
Q2 | $505K | Sell |
9,139
-5,030
| -36% | -$241K | ﹤0.01% | 3315 |
|
|
2025
Q1 | $685K | Sell |
14,169
-5,296
| -27% | -$222K | ﹤0.01% | 3006 |
|
|
2024
Q4 | $751K | Sell |
19,465
-829
| -4% | -$36.1K | ﹤0.01% | 3018 |
|
|
2024
Q3 | $913K | Buy |
20,294
+16,597
| +449% | +$671K | ﹤0.01% | 2550 |
|
|
2024
Q2 | $128K | Sell |
3,697
-43,536
| -92% | -$1.28M | ﹤0.01% | 3234 |
|
|
2024
Q1 | $1.37M | Sell |
47,233
-24,665
| -34% | -$671K | ﹤0.01% | 2296 |
|
|
2023
Q4 | $1.65M | Sell |
71,898
-72,066
| -50% | -$1.26M | ﹤0.01% | 2086 |
|
|
2023
Q3 | $2.4M | Sell |
143,964
-58,346
| -29% | -$1.13M | ﹤0.01% | 1765 |
|
|
2023
Q2 | $5.59M | Sell |
202,310
-35,314
| -15% | -$884K | 0.01% | 1182 |
|
|
2023
Q1 | $5.47M | Buy |
237,624
+146,599
| +161% | +$2.46M | 0.01% | 1197 |
|
|
2022
Q4 | $993K | Sell |
91,025
-145,238
| -61% | -$1.23M | ﹤0.01% | 2168 |
|
|
2022
Q3 | $1.99M | Buy |
236,263
+192,626
| +441% | +$1.82M | ﹤0.01% | 1958 |
|
|
2022
Q2 | $345K | Buy |
43,637
+24,489
| +128% | +$296K | ﹤0.01% | 2855 |
|
|
2022
Q1 | $453K | Sell |
19,148
-19,510
| -50% | -$550K | ﹤0.01% | 2796 |
|
|
2021
Q4 | $1.32M | Buy |
38,658
+30,651
| +383% | +$969K | ﹤0.01% | 2390 |
|
|
2021
Q3 | $142K | Buy |
8,007
+6,406
| +400% | +$273K | ﹤0.01% | 3159 |
|
|
2021
Q2 | $71.9K | Sell |
1,601
-3,037
| -65% | -$100K | ﹤0.01% | 3136 |
|
|
2021
Q1 | $120K | Sell |
4,638
-2,707
| -37% | -$68.5K | ﹤0.01% | 3267 |
|
|
2020
Q4 | $148K | Buy |
7,345
+239
| +3% | +$5.14K | ﹤0.01% | 3023 |
|
|
2020
Q3 | $139K | Buy |
7,106
+6,250
| +730% | +$117K | ﹤0.01% | 2936 |
|
|
2020
Q2 | $15.1K | Sell |
856
-4,630
| -84% | -$58.1K | ﹤0.01% | 3519 |
|
|
2020
Q1 | $38.7K | Buy |
5,486
+3,397
| +163% | +$25.5K | ﹤0.01% | 3663 |
|
|
2019
Q4 | $14.7K | Buy |
2,089
+173
| +9% | +$1.72K | ﹤0.01% | 4073 |
|
|
2019
Q3 | $23K | Buy |
1,916
+1,622
| +552% | +$20.4K | ﹤0.01% | 3887 |
|
|
2019
Q2 | $3.56K | Buy |
294
+290
| +7,250% | +$3.21K | ﹤0.01% | 4278 |
|
|
2019
Q1 | $50 | Sell |
4
-463
| -99% | -$4.09K | ﹤0.01% | 4236 |
|
|
2018
Q4 | $3.14K | Buy |
467
+27
| +6% | +$214 | ﹤0.01% | 3719 |
|
|
2018
Q3 | $4.53K | Hold |
440
| – | – | ﹤0.01% | 4100 |
|
|
2018
Q2 | $2.96K | Sell |
440
-2,163
| -83% | -$16.6K | ﹤0.01% | 4206 |
|
|
2018
Q1 | $22.4K | Sell |
2,603
-245
| -9% | -$4.61K | ﹤0.01% | 3900 |
|
|
2017
Q4 | $59.2K | Buy |
2,848
+2,190
| +333% | +$38.9K | ﹤0.01% | 3571 |
|
|
2017
Q3 | $11.6K | Sell |
658
-65
| -9% | -$900 | ﹤0.01% | 3826 |
|
|
2017
Q2 | $8.18K | Buy |
723
+702
| +3,343% | +$7.51K | ﹤0.01% | 3983 |
|
|
2017
Q1 | $269 | Sell |
21
-342
| -94% | -$5.51K | ﹤0.01% | 3931 |
|
|
2016
Q4 | $7.98K | Buy |
363
+92
| +34% | +$2.05K | ﹤0.01% | 3552 |
|
|
2016
Q3 | $5.73K | Buy |
+271
| New | +$3.7K | ﹤0.01% | 3360 |
|
Other funds holding PTGX
FCM
RI
JJ
BNP Paribas Financial Markets's PTGX Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Protagonist Therapeutics (PTGX) stake by 55% in Q2 2026, buying an estimated $11.2M and bringing the position to 301,472 shares worth $37M. The position accounts for 0.01% of the portfolio, ranked #916.
BNP Paribas Financial Markets first reported a position in PTGX in Q3 2016 and has held it in 40 quarters since. 316 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.
- BNP Paribas Financial Markets held 301,472 shares of Protagonist Therapeutics worth $37M as of Q2 2026.
- BNP Paribas Financial Markets bought 106,942 Protagonist Therapeutics shares in Q2 2026, an estimated $11.2M.
- Protagonist Therapeutics made up 0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #916 holding.
- BNP Paribas Financial Markets first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 40 quarters since.
- 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.